Brain Tumor News!

Note: The comments under each article title are the opinion of our president, Al Musella, DPM,
and do not reflect official policy of the Musella Foundation!

05/26/02 Role of temozolomide (TMZ) for brain relapsed tumors: preliminary results Use of temodar as sole chemotherapy agent showed positive results in pts who had already had surgery, radiotherapy and chemotherapy and had recurrence of tumor.        

05/26/02 Five years of glioblastoma multiforme (GBM) phase II trials at the radiation therapy oncology group (RTOG) Comparison of five experimental chemotherapies to BCNU results over 5 years.        

05/26/02 Is stereotactic radiotherapy adequate treatment for atypical and malignant meningiomas? Stereotatic radiotherapy alone was associated with poor tumor control.        

05/26/02 Cyclooxygenase-2 (COX-2) expression in human meningioma: correlation with malignant progression and potential target The association of COX-2 and meningioma phenotype is unique and represents a potential area for therapeutic intervention with selective COX-2 inhibitors, either alone or in combination with radiation therapy.        

05/26/02 Comparison of mixed anaplastic oligoastrocytoma and high-grade astrocytoma in North Central Cancer Treatment Group (NCCTG) clinical trials of high-grade glioma Study breaks down survival rate based on category of tumor.        

05/26/02 A phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral etoposide combined with radiation therapy in the treatment of glioblastoma (GBM) No significant improvement in survival rate with this pre-irradiation chemotherapy.        

05/26/02 Phase II trial with carboplatin (CBCDA) and etoposide (VP-16) in recurrent high grade gliomas In this clinical trial CBCDA + VP-16 has shown activity in recurrent AA and GBM, with a good toxicity profile.        

05/26/02 Phase II study of temozolomide (TMZ) without radiotherapy in newly diagnosed glioblastoma multiforme (GBM) in an elderly population TMZ without radiotherapy may offer a safe, convenient, and efficient therapeutic alternative in elderly patients with newly diagnosed GBM.        

05/26/02 First line chemotherapy with cisplatin plus fractionated temozolomide (bid) in recurrent glioblastoma (GBM). This new regimen of DDP plus bid TMZ is effective in chemonaive recurrent GBM, with acceptable toxicity        

05/26/02 A phase I study of temozolomide (Temodar) and escalating doses of oral VP-16 for adults with recurrent malignant glioma The maximum tolerated dose of this combination in this heavily treated group of patients with recurrent malignant glioma is temozolomide 150 mg/m2/d for 5 days + oral VP-16 50 mg/m2/d for 12 days.        

05/26/02 The role of 3-step radioimmunotherapy (RIT) as adjuvant treatment in malignant gliomas Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly in glioblastoma where it impedes progression, prolonging time to relapse and overall survival.        

05/26/02 Phase II trial of BCNU, temozolamide (TMZ) plus intraarterial cisplatin (CDDP) in unresectable or recurrent high grade glioma Preliminary data suggest that this chemotherapy combination is active and well tolerated.        

05/26/02 Use of magnetic resonance spectroscopy (MRS) in malignant gliomas treated with temozolomide (TMZ) MRS may increase sensitivity of traditional MRI techniques for detecting tumor progression or response and our observations of tumor response by MRI suggest that multi-voxel MRS is crucial to evaluating response for inhomogeneous tumors (such as oligodendrogliomas).        

05/26/02 Phase II trial of motexafin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) Motexafin gadolinium in combination with cranial radiation is tolerable for GBM patients; early follow-up shows a 6 month survival of 84%        

05/24/02 Convection-enhanced intra-tumoral delivery of taxol for recurrent glioblastoma. Results of a phase I clinical study.
Conclusion: Significant antitumor responses were seen.        

05/24/02 Novel use of Gliadel for gliomas        

05/17/02 The Tour of the Lower 48: fundraiser for brain tumor research        

05/16/02 Live Chat: Sunday May 19, 8-9pm. Virtualtrials.com Topic: Gamma Knife For Brain Tumors. Hosted by: Rosario Musella, MD, FACS, a neurosurgeon at Bayfront Medical Center, St. Petersburg, Florida        

05/16/02 GE Medical Systems Signs Agreements With NeuroSource Inc. To Expand Consulting Offerings Available to Neuroscience Programs Focus on Six Sigma-based performance improvement tools and techniques        

---

Displaying Stories 6081 to 6100 of 7668
Previous 20           Next 20